By Ethan Covey
Grifols, headquartered in Barcelona, Spain, announced the release of a new vial size of HyperRAB human rabies immune globulin (HRIG).
HyperRAB, which was initially approved in the United States in 1974, is used for post-exposure prophylaxis (PEP) in patients who may have been exposed to rabies.